Loading…
Hosted by Unknown Host · 🇺🇸 US · EN · 33 episodes
Established thought leaders with verified media credentials.
The FLASCO OncoPod is a podcast series that brings you engaging interviews and conversations with oncology champions and thought leaders. Each episode explores important topics in cancer care, from the latest clinical advancements to FLASCO events and initiatives. Whether it’s discussing groundbreaking research, policy updates, or sharing personal stories from members, the OncoPod keeps oncology professionals informed and connected. It’s your go-to source for staying up-to-date on FLASCO’s efforts to support and strengthen the oncology community across Florida.
Unknown Host hosts FLASCO OncoPod, a business show with 33 episodes published.
In this episode of the FLASCO OncoPod, Drew Piers, President of Sachs Media, explores the powerful role advocacy, storytelling, and strategic communications play in advancing cancer care beyond the clinic. Drawing on yea
Hepatocellular carcinoma (HCC) continues to present unique challenges for oncology teams, requiring coordinated multidisciplinary care and an evolving understanding of both liver disease and cancer management. In this ep
In this episode of the FLASCO OncoPod, Dr. McDonough moderates a discussion with Dr. Wenk, Dr. Glick, and Dr. Patel, of Florida Cancer Specialists & Research Institute on the evolving role of community oncology and how t
In this episode of the FLASCO OncoPod, host Dr. Edgardo Santos, President of the Florida Society of Clinical Oncology (FLASCO), leads a multidisciplinary discussion on the evolving role of immunohistochemistry (IHC) in p
In this episode of the FLASCO OncoPod, host Dr. Edgardo Santos , President of the Florida Society of Clinical Oncology (FLASCO), leads a multidisciplinary discussion on the evolving role of immunohistochemistry (IHC) in
In this episode of the FLASCO OncoPod, host Dr. Edgardo Santos , President of the Florida Society of Clinical Oncology (FLASCO), leads a multidisciplinary discussion on the evolving role of immunohistochemistry (IHC) in
In this episode of the FLASCO OncoPod, host Dr. Edgardo Santos , President of the Florida Society of Clinical Oncology (FLASCO), leads a multidisciplinary discussion on the evolving role of immunohistochemistry (IHC) in
The treatment landscape for chronic lymphocytic leukemia (CLL) has transformed dramatically over the past decade, creating new opportunities and new questions for clinicians managing this increasingly complex disease. In
Join Scott E. Jordan, MD, FACOG, gynecologic oncologist at Broward Health, as he breaks down the most important endometrial cancer updates presented at the 2026 Society of Gynecologic Oncology (SGO) Annual Meeting. In th
What does it take to successfully navigate the business of oncology while continuing to deliver exceptional patient care? In this episode of the FLASCO OncoPod, Dr. Robin Zon joins Dr. Jorge Garcia for a thoughtful conve
In this final episode of the FLASCO OncoPod series, Drs. Jaglal, Fu, and Shahzad shift focus to the long-term management of atypical hemolytic uremic syndrome (aHUS) in oncology patients. Building on the diagnostic and a
In this episode of the FLASCO OncoPod, Drs. Jaglal, Fu, and Shahzad explore the real-world challenges of managing suspected thrombotic microangiopathy (TMA) in oncology patients. Building on a complex multiple myeloma ca
Atypical hemolytic uremic syndrome (aHUS) in patients with malignancy or undergoing cancer-directed therapy is likely under-recognized, yet early identification can have a profound impact on patient outcomes. In this FLA
Join moderator Caroline DiCristo, PharmD, Associate Medical Director – Zanidatamab of Jazz Pharmaceuticals, alongside Dr. Noman Ashraf, MD, of Tampa General Hospital Cancer Institute for the final installment of the Adva
Join moderator Caroline DiCristo, PharmD, Associate Medical Director – Zanidatamab of Jazz Pharmaceuticals, alongside Dr. Noman Ashraf of Tampa General Hospital Cancer Institute and Dr. Umair Majeed of Mayo Clinic in Jac
Join moderator Caroline DiCristo, PharmD, Associate Medical Director – Zanidatamab of Jazz Pharmaceuticals, alongside Dr. Paresh Patel and Dr. Masoumeh Ghayouri for the second installment of the Advancing Care in GI and
Join moderator Caroline DiCristo, PharmD, Associate Medical Director – Zanidatamab of Jazz Pharmaceuticals and GI Oncologist Dr. Umair Majeed of Mayo Clinic in Jacksonville for the first installment of the Advancing Care
Join Dr. Edgardo Santos and Dr. Luis Raez for a practical discussion on first-line decision-making in EGFR-mutated lung cancer and how early treatment choices shape survival, sequencing, and patient experience. This epis
Join Dr. Paresh Patel and Dr. Masoumeh Ghayouri for a crucial conversation on the complexities of HER2 testing in Gastrointestinal (GI) cancers, including Gastroesophageal Adenocarcinoma (GEA) and Biliary Tract Cancer (B
Join Dr. Paresh Patel and Dr. Masoumeh Ghayouri for a crucial conversation on the complexities of HER2 testing in Gastrointestinal (GI) cancers, including Gastroesophageal Adenocarcinoma (GEA) and Biliary Tract Cancer (B
Dr. Jorge Garcia
City Engineer · Case Western Reserve University School of Medicine
2 appearances on this show
Dr. Lamees Saeed
Tampa General Hospital Cancer Institute
3 appearances on this show
Dr. Ana Sandoval
Herbert Wertheim Cancer Institute at Baptist Health South Florida
3 appearances on this show
Dr. Nathalie McKenzie
AdventHealth Cancer Institute
3 appearances on this show
Dr. Jesus Fabregas
Memorial Cancer Institute
3 appearances on this show
Javier Pinilla-Ibarz
Moffitt Cancer Center
1 appearance on this show
Scott E. Jordan, MD, FACOG
Broward Health
1 appearance on this show
Dr. Noman Ashraf
Tampa General Hospital Cancer Institute
2 appearances on this show
Dr. Umair Majeed
Mayo Clinic
1 appearance on this show
Caroline DiCristo
Jazz Pharmaceuticals
1 appearance on this show
Umair Majeed
Mayo Clinic
1 appearance on this show
Dr. Neil M. Iyengar
Winship Cancer Institute at Emory University
1 appearance on this show
Detected from recent episode content. Sponsor presence is a real signal of listener purchasing power and show monetisation.
No public pitch examples yet for this show.
Generate your own personalised pitchBased on semantic analysis of episode topics and host coverage, this show is a strong guest fit for executives in:
Industry fit is computed by PitchCentric using vector embeddings of the show's episode catalog.
Shows with the most semantically similar episode content. Pitch one, pitch all; producers cluster.
To pitch FLASCO OncoPod, visit https://flasco.org/oncology-professionals/podcasts/ for contact information, then craft a tight one-paragraph hook that ties your expertise to a gap in their recent business coverage.
FLASCO OncoPod is hosted by Unknown Host. The show is categorised under Business (fitness) and has published 33 episodes.
FLASCO OncoPod has published 33 episodes.
FLASCO OncoPod regularly covers Business, Non-profit, Health, Fitness, Medicine. It sits in the Business category, with a fitness focus.
FLASCO OncoPod is accessible for guests with genuine business expertise. A personalised, episode-aware pitch will still outperform a generic one every time.
FLASCO OncoPod hasn't explicitly signalled guest openness in recent episodes. That doesn't rule out pitching. your hook just needs to be especially compelling and relevant to their recent content.
Episodes of FLASCO OncoPod average 19 minutes. a focused format where a clear narrative arc and tight preparation matter most.
Our data rates FLASCO OncoPod's guest bar at 80/100 (Premium tier). Established thought leaders with verified media credentials. Sign in to PitchCentric to see how your own Pod Score compares against this show.
Methodology. Booking Probability™ blends Listen Score, 30-day Virality, open-to-guests detection, and Apple ratings. Data refreshed every 60 minutes. Listen Score and Booking Probability are calculated by PitchCentric. Last enriched yesterday.